carecentrix

Provider Newsflash
March 2024

FDA Recall – Treprostinil injection by Par Pharmaceutical

Purpose of this communication:

- We are writing to inform you that effective immediately the FDA has posted notice of a voluntary nationwide recall of Treprostinil by Par Pharmaceutical, lot 57014 of Treprostinil Injection 20 mg/20mL (1 mg/mL) distributed nationwide to wholesalers and hospitals from June 16, 2022, through October 17, 2022. This recall is due to the potential for the presence of silicone particulates in the product solution.

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/par-pharmaceutical-issues-voluntary-nationwide-recall-one-lot-treprostinil-injection-due-potential?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.